MMP14: A Potential Drug Target for Cancer (G4323)

Target Name: MMP14

NCBI ID: G4323

MMP14

MMP14: A Potential Drug Target for Cancer

Matrix metalloproteinase (MMP) 14 (MMP14) is a protein that is expressed in various tissues throughout the body, including the extracellular matrix (ECM), bone, and soft tissues. It is a member of the MMP family, which includes 14 different proteins that are involved in ECM degradation and remodeling. MMP14 is known for its role in the regulation of cellular processes such as cell adhesion, migration, and invasion, and is involved in the development and progression of various diseases, including cancer.

MMP14 has been identified as a potential drug target in the field of cancer, due to its involvement in the regulation of cell signaling pathways that are critical for cancer growth and progression. MMP14 has been shown to play a role in the development and progression of various types of cancer, including breast, ovarian, and prostate cancer.

One of the key mechanisms by which MMP14 contributes to cancer development is its role in the regulation of cell adhesion and migration. MMP14 has been shown to play a role in the production of a protein called nano-particles, which are small, non-covalent particles that are produced by the degradation of ECM components by MMP14. Nano-particles have been shown to be able to interact with various cell signaling pathways, including the TGF-β pathway, which is involved in cell adhesion and migration.

In addition to its role in cell adhesion and migration, MMP14 has also been shown to contribute to the development and progression of cancer by its role in the regulation of cell signaling pathways that are critical for overall cellular growth and division. play a role in the production of a protein called protamine, which is involved in the regulation of cell cycle progression and the G1/S checkpoint.

MMP14 has also been shown to contribute to the development and progression of cancer by its role in the regulation of cellular processes that are critical for the formation of new blood vessels. MMP14 has also been shown to play a role in the production of a protein called matrix -assisted delivery (MAD), which is involved in the delivery of various ECM components to new tissues.

In conclusion, MMP14 is a protein that has been shown to play a critical role in the development and progression of cancer. Its involvement in the regulation of cell adhesion, migration, and cellular signaling pathways makes it an attractive target for drug development. Further research is needed to fully understand the role of MMP14 in cancer development and to develop effective therapies that target this protein.

Protein Name: Matrix Metallopeptidase 14

Functions: Endopeptidase that degrades various components of the extracellular matrix such as collagen. Activates progelatinase A. Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development (By similarity). May be involved in actin cytoskeleton reorganization by cleaving PTK7 (PubMed:20837484). Acts as a positive regulator of cell growth and migration via activation of MMP15. Involved in the formation of the fibrovascular tissues in association with pro-MMP2 (PubMed:12714657). Cleaves ADGRB1 to release vasculostatin-40 which inhibits angiogenesis (PubMed:22330140)

The "MMP14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MMP14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets